In a report released yesterday, Michael Wiederhorn from Oppenheimer maintained a Buy rating on Amedisys (AMED), with a price target of $140. The company’s shares closed yesterday at $127.82.
Wiederhorn commented:
“Amedisys reported Q1:19 adj. EPS of $1.11 (GAAP: $0.95), well ahead of OPCO/ Street consensus of $0.84/$0.89E. Excluded results primarily consist of $0.13 from acquisition costs. Results were driven by impressive 28% home health EBITDA growth, largely driven by cost controls (margins +250 bps y-y). Despite the strong beat, AMED conservatively maintained FY2019 EPS guidance of $3.98-$4.09. While the initial Compassionate Care contribution is expected to remain modest, the company projects a huge ramp in EBITDA in 2019/2020. Following the quarter, we are increasing our FY2019/FY2020 EPS estimates to $4.09/$4.47 from $4.04/$4.45.”
According to TipRanks.com, Wiederhorn is a 5-star analyst with an average return of 13.9% and a 65.1% success rate. Wiederhorn covers the Services sector, focusing on stocks such as Cross Country Healthcare, Addus Homecare Corp, and Community Health.
Currently, the analyst consensus on Amedisys is a Moderate Buy with an average price target of $134.
See today’s analyst top recommended stocks >>
Amedisys’ market cap is currently $4.09B and has a P/E ratio of 35.83. The company has a Price to Book ratio of 8.49.
Based on the recent corporate insider activity of 57 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Amedisys, Inc. engages in the provision of healthcare services. It operates through the following business segments: Home Health, Hospice, and Personal Care. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury, or surgery.
